Malaguarnera M, Di Fazio I, Laurino A, Romeo M A, Giugno I, Trovato B A
Département de médecine interne et de gériatrie, universita' di Catania, Italie.
Bull Cancer. 1996 May;83(5):379-84.
Interleukin 6 (IL-6) is a pleiotropic cytokine which possesses a broad spectrum of action in diverse pathological conditions. It is mainly produced and metabolised in the liver where it carries out one of its best known actions in the mediation of the acute phase response. We studied its behaviour in hepatocellular carcinoma to evaluate its clinical prognostic role. We determined serum IL-6 concentrations in 39 patients with hepatocarcinoma (27 males and 12 females) and 25 healthy controls (15 males and ten females). Our results showed a significant increase in serum IL-6 concentrations in hepatocarcinoma subjects compared with controls (P < 0.005) and an elevated positive correlation (r = 0.616) between IL-6 and size of the hepatocarcinoma. Our study demonstrated that IL-6 is able to influence hepatocarcinoma progression by acting as an autocrine tumoral growth factor and depleting immune surveillance.
白细胞介素6（IL-6）是一种多效细胞因子，在多种病理状况下具有广泛的作用。它主要在肝脏中产生和代谢，在介导急性期反应方面发挥其最为人熟知的作用之一。我们研究了其在肝细胞癌中的表现，以评估其临床预后作用。我们测定了39例肝癌患者（27例男性和12例女性）和25名健康对照者（15例男性和10例女性）的血清IL-6浓度。我们的结果显示，与对照组相比，肝癌患者血清IL-6浓度显著升高（P < 0.005），并且IL-6与肝癌大小之间存在高度正相关（r = 0.616）。我们的研究表明，IL-6能够作为一种自分泌肿瘤生长因子并削弱免疫监视，从而影响肝癌进展。
